Sign inCreate account

Report workspace tools

NCT03128411COMPLETEDanonymous

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Sponsor

Source record

Pfizer

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Bosutinib

Indication / condition

AI-normalized

Leukemia, Chronic Myelogenous

Intervention

Source record

Bosutinib

Source & freshness

Source record

NCT ID

NCT03128411

Original source

ClinicalTrials.gov

Source last updated

May 19, 2022

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03128411

Title

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Sponsor

Pfizer

Status

COMPLETED

Phase

PHASE2

Condition raw

Leukemia, Chronic Myelogenous

Condition normalized

Leukemia, Chronic Myelogenous

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Bosutinib

Target normalized

Bosutinib

Interventions

Bosutinib

Public preview

Source record

Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03128411

Status

COMPLETED

Phase

PHASE2

Sponsor

Pfizer

Executive brief

Investment-Ready Snapshot

Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 19, 2022
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03128411

Indication

Leukemia, Chronic Myelogenous

Modality

small molecule

Target

Bosutinib

Intervention

Bosutinib

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.